ICOS: Reducing First, Subsequent, and Total CV Events in Dyslipidemia Management

Reduction in first, subsequent, and total CV events with Icosapent ethyl¹

30% RRR IN TOTAL EVENTS

RR=0.7 (95% CI, 0.62-0.78) P=0.000000000036

To explore how ICOS can assist your CV patients and connect you with a medical rep, please tick the box below:

I acknowledge that my contact details may be used for this purpose*

GGI-CO-A1-AQS-300040480-ELC-H24-1448
IPE: Icosapent ethyl; AHA: American Heart Association (AHA) Science Advisory 2020; NLA: National Lipid Association (NLA) Scientific Statement 2019; T2DM: Type 2 diabetes; CAD: Coronary Artery Disease; TG: Triglyceride; CVD: Cardiovascular Diseases; CV: Cardiovascular; LDL-C: Low-density lipoprotein-cholesterol
Reference:
1.	Bhatt DL, Steg PG, Miller M, et al; on behalf of the REDUCE-IT Investigators. Effects of icosapent ethyl on total ischemic events: from REDUCE-IT. J Am Coll Cardiol. 2019;73(22):2791-2802.

Repatha Gateway - Case of Gauri: Recent STEMI and PCI

Gauri, a patient with inferior STEMI, came to ER, underwent PCI, and was hospitalized. Despite...

Tanmay, a male patient with a history of recurrent myocardial infarctions (MI), presents with severe...

Mr. Basu’s case: a 54-year-old patient with diabetes, hypertension, and hyperlipidemia on statins, evaluated with...

Explore Venu’s journey on statin therapy, where ICOS showed a 25% risk reduction in 5-Point...